by MM360 Staff | May 9, 2025 | Myeloma News
Source: Pharmacy Times articles Abemaciclib and ribociclib have various risks and benefits in treating early breast cancer, highlighting the importance of patient-provider communication. Read More
by MM360 Staff | May 9, 2025 | Myeloma News
Source: Pharmacy Times articles A panelist discusses how emerging advancements in non–small cell lung cancer (NSCLC) treatment include the anticipated FDA approval of subcutaneous amivantamab, which would significantly reduce infusion-related reactions seen in the...
by MM360 Staff | May 8, 2025 | Myeloma News
Source: Pharmacy Times articles New research reveals that B vitamins and choline may slow glaucoma progression, offering hope for innovative treatments beyond traditional methods. Read More
by MM360 Staff | May 8, 2025 | Myeloma News
Source: Pharmacy Times articles With this approval, avutometinib/defactinib has become the first and only FDA-approved treatment for patients with recurrent low-grade serous ovarian cancer (LGSOC). Read More
by MM360 Staff | May 8, 2025 | Myeloma News
Source: Pharmacy Times articles The fixed-dose combination yielded a 49% greater reduction in low density lipoprotein cholesterol (LDL-C) compared with placebo. Read More
by MM360 Staff | May 8, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More